Can adagrasib (Krazati) be used in pediatric patients and analysis of related safety data

Adagrasib (Krazati) is a KRAS G12C mutation inhibitor. Currently, its approved indications in the United States, Europe and other countries are limited to adult patients, and it is mainly used for locally advanced or metastatic non-small cell lung cancer and other diseases. According to the official instructions, the safety and effectiveness of adagrasib in children have not yet been determined, and there are currently no large-scale clinical data for pediatric patients. Therefore, this drug is not recommended for use in children under the age of 18 unless used in clinical studies that have undergone ethical review and strict supervision.

Although there are no clinical data on use in children, adult studies may provide some guidance. In clinical trials such as KRYSTAL-1, the most common adverse reactions of adagrasib include diarrhea, nausea, vomiting, elevated transaminases, and fatigue. Some patients have experienced prolonged QTc interval, impaired renal function, or severe infection, requiring drug discontinuation or dose reduction. The toxicities observed in these adult patients may be more pronounced in children, particularly with regard to cardiac electrophysiology and hepatic and renal metabolism, and thus adult doses or regimens cannot be directly replicated.

During the growth and development period, the absorption, distribution, metabolism and excretion characteristics of drugs in children are significantly different from those in adults, and drug exposure may deviate from expectations, leading to uncertainty in efficacy and adverse reactions. In addition, adagrasib, as a targeted drug, may have potential effects on developing organs, cardiac electrical activity, and the reproductive system. Currently, there is a lack of sufficient animal and clinical research data to support its use in children. Therefore, there are greater risks when using this drug in children.

At this time, adagrasib is not recommended for routine use in pediatric patients. If there is a clinical need, it must be carried out in a qualified medical institution, under ethically approved clinical research or special drug application, and electrocardiogram, liver and kidney function and adverse reactions must be strictly monitored. Doctors should fully explain the risks of medication to children and their families and follow regulatory requirements. If research data specifically for pediatric patients are released in the future, the relevant indications and medication guidelines may be further adjusted.

Reference materials:https://www.drugs.com/